Неалкогольная жировая болезнь печени: коморбидность, клиническое значение и методы диагностики фиброза печени

Автор: Маршалко Д.В., Пчелин И.Ю., Шишкин А.Н.

Журнал: Juvenis scientia @jscientia

Рубрика: Медицинские науки

Статья в выпуске: 2, 2018 года.

Бесплатный доступ

В статье проанализированы современные научные данные о патогенетических и клинико-эпидемиологических аспектах неалкогольной жировой болезни печени (НАЖБП), которая за последнее десятилетие вышла на первое место по распространенности среди заболеваний печени в России. Рассмотрены наиболее актуальные проблемы коморбидности при НАЖБП. Дана сравнительная характеристика различных методов диагностики фиброза печени с описанием их преимуществ и недостатков. Суммированы данные последних лет о прогностическом значении индексов, используемых для неинвазивной оценки фиброза печени при НАЖБП.

Неалкогольная жировая болезнь печени, фиброз печени, стеатогепатит, цирроз печени, транзиторная эластография, шкала nfs, шкала fib-4, биопсия печени, метаболический синдром, инсулинорезистентность

Короткий адрес: https://readera.ru/14110472

IDR: 14110472

Список литературы Неалкогольная жировая болезнь печени: коморбидность, клиническое значение и методы диагностики фиброза печени

  • EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease//J. Hepatol. 2016. Vol. 64. P. 1388-1402.
  • Rinella M.E. Nonalcoholic fatty liver disease: a systematic review/JAMA. 2015. Vol. 313. P. 2263-2273.
  • Vernon G., Baranova A., Younossi Z.M. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults//Aliment. Pharmacol. Ther. 2011. Vol. 34. P. 274-285.
  • Диагностика и лечение неалкогольной жировой болезни печени: методические рекомендации для врачей/под ред. акад. В.Т. Ивашкина . URL: https://rsls.ru/files/Guidelines-RSLS-NASH-2016-01-03.pdf.
  • Adejumo A., Alliu S., Ajayi T. O. et al. Cannabis use is associated with reduced prevalence of non-alcoholic fatty liver disease: A cross-sectional study//PLoS One. 2017. Vol. 12. e0176416.
  • Ekstedt M., Hagström H., Nasr P. et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up/Hepatology. 2015. Vol. 61. P. 1547-1554.
  • Targher G., Day C. P., Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease/N. Engl. J. Med. 2010. Vol. 363. P. 1341-1350.
  • Lee S.B., Park G.M., Lee J Y et al. Association between nonalcoholic fatty liver disease and subclinical coronary atherosclerosis: An observational cohort study/J. Hepatol. 2017. In press.
  • Musso G., Gambino R., Tabibian J. H. et al. Association of Non-alcoholic Fatty Liver Disease with Chronic Kidney Disease: A Systematic Review and Meta-analysis/PLoS Med. 2014. Vol. 11. e1001680.
  • Mikolasevic I., Racki S., Bubic I. et al. Chronic kidney disease and nonalcoholic Fatty liver disease proven by transient elastography//Kidney Blood Press. Res. 2013. Vol. 37. P. 305-310.
  • Kim G.A., Lee H.C., Choe J. et al. Association between non-alcoholic fatty liver disease and cancer incidence rate//J. Hepatol. 2018. Vol. 68. P. 140-146.
  • Pár A., Pár G. Non-alcoholic fatty liver disease and hepatocellular carcinoma //Orv. Hetil. 2016. Vol. 157. P. 987-994.
  • Calzadilla Bertot L., Adams L. A. The Natural Course of Non-Alcoholic Fatty Liver Disease//Int. J. Mol. Sci. 2016. Vol. 17. E774.
  • Lim H.-W., Bernstein D.E. Risk Factors for the Development of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Genetics//Clin. Liv. Dis. 2018. Vol. 22. P. 39-57.
  • Borrelli A., Bonelli P., Tuccillo F. M. Role of gut microbiota and oxidative stress in the propression of non-alcoholic fatty liver disease to hepatocarcinoma: Current and innovative therapeutic approaches//Redox Biol. 2018. Vol. 15. P. 467-479.
  • Singh S., Allen A. M., Wang Z. et al. Fibrosis Progression in Nonalcoholic Fatty Liver vs Nonalcoholic Steatohepatitis: A Systematic Review and Meta-analysis of Paired-Biopsy Studies//Clin. Gastroenterol. Hepatol. 2015. Vol. 13. P. 643-654.
  • Dulai P. S., Singh S., Patel J. et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis//Hepatology. 2017. Vol. 65. P. 1557-1565.
  • Hagström H., Nasr P., Ekstedt M. et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD//J. Hepatol. 2017. Vol. 67. P. 1265-1273.
  • Sesti G., Sciacqua A., Fiorentino T.V. et al. Association between noninvasive fibrosis markers and cardio-vascular organ damage among adults with hepatic steatosis//PLoS One. 2014. Vol. 9. e104941.
  • Spengler E.K., Loomba R. Recommendations for Diagnosis, Referral for Liver Biopsy, and Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis//Mayo Clin. Proc. 2015. Vol. 90. P. 1233-1246.
  • Scott R., Guha I. N. Non-invasive monitoring of liver fibrosis//Br. Med. Bull. 2014. Vol. 112. P. 97-106.
  • Almpanis Z. Evaluation of liver fibrosis: "Something old, something new…"//Ann. Gastroenterol. 2016. Vol. 29. 445-453.
  • Sumida Y., Nakajima A., Itoh Y. Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis//World J. Gastroenterol. 2014. Vol. 20. P. 475-485.
  • Bedossa P., Patel K. Biopsy and Noninvasive Methods to Assess Progression of Nonalcoholic Fatty Liver Disease//Gastroenterology. 2016. Vol. 150. P. 1811-1822.
  • Papastergiou V., Tsochatzis E., Burroughs A. K. Non-invasive assessment of liver fibrosis//Ann. Gastroenterol. 2012. Vol. 25. P. 218.
  • Karim M. F, Al-Mahtab M, Rahman S. et al. Non-alcoholic Fatty Liver Disease (NAFLD) -A Review//Mymensingh Med. J. 2015. Vol. 24. P. 873-880.
  • Festi D., Schiumerini R., Marzi L. et al. Review article: the diagnosis of non-alcoholic fatty liver disease -availability and accuracy of non-invasive methods//Alim. Pharmacol. Ther. 2013. Vol. 37. P. 392-400.
  • Kim D., Kim W. R., Talwalkar J. A. et al. Advanced fibrosis in nonalcoholic fatty liver disease: noninvasive assessment with MR elastography//Radiology. 2013. Vol. 268. P. 411-419.
  • Myers R. P., Pomier-Layrargues G., Kirsch R. et al. Discordance in fibrosis staging between liver biopsy and transient elastography using the FibroScan XL probe//J. Hepatol. 2012. Vol. 56. P. 564-570.
  • Mikolasevic I., Orlic L., Franjic N. et al. Transient elastography (FibroScan(®)) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease -Where do we stand//World J. of Gastroenterol. 2016. Vol. 22. P. 7236-7251.
  • Hashemi S.-A., Alavian S.-M., Gholami-Fesharaki M. Assessment of transient elastography (FibroScan) for diagnosis of fibrosis in non-alcoholic fatty liver disease: A systematic review and meta-analysis//Casp. J. Intern. Med. 2016. Vol. 7. P. 242-252.
  • Abenavoli L., Beaugrand M. Transient elastography in non-alcoholic fatty liver disease//Ann. Hepatol. 2012. Vol. 11. P. 172-178.
  • Angulo P., Hui J. M., Marchesini G. et al. The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD//Hepatology. 2007. Vol. 45. P. 846-854.
  • Angulo P., Bugianesi E., Bjornsson E. S. et al. Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease//Gastroenterology. 2013. Vol. 145. P. 782-789.
  • Musso G., Gambino R., Cassader M. et al. Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity/Ann. Med. 2011. Vol. 43. P. 617-649.
  • McPherson S., Stewart S. F., Henderson E. et al. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease//Gut. 2010. Vol. 59. P. 1265-1269.
  • Castera L. Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease//Semin. Liver Dis. 2015. Vol. 35. P. 291-303.
  • Petta S., Wong V.W., Cammà C. et al. Serial combination of non-invasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with NAFLD//Alim. Pharmacol. Ther. 2017. Vol. 46. P. 617-627.
  • Chang Y., Jung H. S., Yun K. E. et al. Cohort study of non-alcoholic fatty liver disease, NAFLD fibrosis score, and the risk of incident diabetes in a Korean population//Am. J. Gastroenterol. 2013. Vol. 108. P. 1861-1868.
  • Gentili A., Daviddi G., De Vuono S. et al. Non-alcoholic fatty liver disease fibrosis score and preclinical vascular damage in morbidly obese patients//Dig. Liver Dis. 2016. Vol. 48. P. 904-908.
  • Jaruvongvanich V., Wijarnpreecha К., Ungprasert P. The utility of NAFLD fibrosis score for prediction of mortality among patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of cohort study//Clin. Res. Hepatol. Gastroenterol. 2017. Vol. 41. P. 629-634.
  • Yoshihisa A., Sato Y., Yokokawa T. et al. Liver fibrosis score predicts mortality in heart failure patients with preserved ejection fraction//ESC Heart Fail. 2017. In press DOI: 10.1002/ehf2.12222
  • Wijarnpreecha K., Thongprayoon C., Scribani M. et al. Noninvasive fibrosis markers and chronic kidney disease among adults with nonalcoholic fatty liver in USA//Eur. J. Gastroenterol. Hepatol. 2017. In press DOI: 10.1097/MEG.0000000000001045
  • Xu H. W, Hsu Y. C, Chang C. H. et al. High FIB-4 index as an independent risk factor of prevalent chronic kidney disease in patients with nonalcoholic fatty liver disease//Hepatol. Int. 2016. Vol. 10. P. 340-34.
Еще
Статья научная